礼来收购非阿片类疼痛疗法初创公司SiteOne

Core Insights - Eli Lilly has reached a definitive agreement to acquire SiteOne Therapeutics, a private biotechnology company focused on developing sodium channel small molecule inhibitors for pain and other neuronal hyperexcitability disorders, with shareholders potentially receiving up to $1 billion in cash [1][2] Group 1: Acquisition Details - The acquisition includes STC-004, a Nav1.8 inhibitor currently in Phase 2 clinical preparation for pain treatment, which may represent a new generation of non-opioid chronic pain therapies [1] - SiteOne shareholders will receive up to $1 billion in cash, which includes upfront payments and subsequent payments contingent upon achieving certain regulatory and commercial milestones [1] Group 2: Company Vision and Commitment - SiteOne has dedicated over a decade to advancing a vision of providing safer and more effective non-opioid therapies for patients suffering from pain and other sensory hyperexcitability disorders [2] - The CEO of SiteOne expressed confidence that Eli Lilly's global capabilities and leadership in neuroscience will accelerate the realization of STC-004 and the broader platform's potential [2]